- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
January 15, 2021Robins Kaplan Partners Named to IAM Strategy 300 Global Leaders Guide
-
January 12, 20212025 Goals - Our commitment to Inclusion, Diversity, and Equity
-
January 5, 2021Litigator Mark Hallberg Joins Robins Kaplan LLP
-
January 28, 2021COVID-19: The Show Did Not Go On
-
February 9, 2021Smart Phone Privacy and Data Security – How to Assess and Minimize Risk in the Current Reality
-
March 6, 2021With Our Voices 2021 Arc Gala
-
2020Clear Evidence Clarified
-
December 27, 2020Covid-19 Relief Bill Provides Long-Awaited Funding to Small Businesses and Individuals
-
December 17. 2020Covid-19 Divorce and Marital Property Agreements
-
January 21, 2021Financial Daily Dose 1.21.2021 | Top Story: Wall Street Greets Biden Administration With Rally, Records on Stimulus Hopes
-
January 20, 2021Financial Daily Dose 1.20.2021 | Top Story: Netflix Hits 200M Subscribers, Halts Massive Borrowing
-
January 19, 2021Financial Daily Dose 1.19.2021 | Top Story: Fiat Chrysler and PSA Group Finalize Merger to Form Auto Behemoth Stellantis NV
Consumer Alert: Lariam Antimalarial Drug and Permanent Neuropsychological Side Effects
August 19, 2013
Attorneys at Robins, Kaplan, Miller & Ciresi are investigating reports of serious neurological and psychiatric side effects associated with mefloquine hydrochloride—a drug used in the prevention and treatment of malaria. Reports have linked the drug to thousands of adverse reports of psychiatric problems, including suicide, attempted suicide, aggression towards others, psychosis, paranoia, hallucinations, anxiety, panic, dizziness, loss of balance, and depression.
On July 29, 2013, the U.S. Food and Drug Administration (FDA) issued a safety alert to doctors and the public regarding updated warnings of long lasting neuropsychiatric side effects associated with mefloquine. The FDA noted that some of these side effects may persist or become permanent. Mefloquine now has a Black Box Warning on its label—most serious kind of warning about potential side effects.
Mefloquine is commonly used by international travelers, including vacationers, military service members, Peace Corps Volunteers, and business travelers. Mefloquine has been a popular antimalarial drug, particularly because consumers need only take the drug once a week rather than daily. Yet, alternative antimalarial medications not associated with permanent neuropsychological side effects exist on the market.
Mefloquine was originally developed by the United States Army and entered the commercial market in 1989. It has also been referred to as Lariam, Mephaquin, or Mefliam. There have been four manufacturers of Mefloquine in the United States market:
- Hoffman La Roche (brand name Lariam)
- Boehringer Ingelheim, Roxane Laboratories (generic version)
- Sandoz Inc. (generic version)
- Teva Pharmaceuticals (generic version)
If you have taken Mefloquine or Lariam and have experienced Mefloquine side effects, please contact the law firm of Robins, Kaplan, Miller & Ciresi for a free consultation. We have attorneys and legal nurse consultants on staff ready to assist you. All calls are kept confidential. You may be entitled to compensation.
© 2013 Robins, Kaplan, Miller & Ciresi L.L.P.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Gary L. Wilson
Partner
Troy Tatting
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.